Early Levothyroxine Post Radioactive Iodine

Overview

About this study

The study will try to answer the question of whether early treatment with levothyroxine at 4 weeks after radioactive iodine for Graves' disease will prevent overt hypothyroidism (low thyroid hormone levels).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  •  All adult patients (ages 18-70 years)
  •  With Graves' Disease
  •  Who will receive RAI for treatment of GD

Exclusion Criteria:

  • Patients with clinically manifest Graves’ Ophthalmopathy
  • Patients with recent (<1 yr.) history of arrhythmias or any history of ventricular arrhythmias
  • Preexistent cardiomyopathy
  • Malnutrition
  • Psychiatric history that could get worse if patient remains persistently hyperthyroid
  • Patients unlikely to return for the planned follow-up visits, to comply with the blood drawing schedule and with the completion of the hypothyroid-HDQL and TQS questionnaires

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Marius Stan, M.D.

Closed for enrollment

Contact information:

Jeanette Laugen

(507)255-8110

Laugen.Jeanette@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20118004

Mayo Clinic Footer